| Not Yet Recruiting | Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory NCT07122648 | Paean Biotechnology Inc. | Phase 2 |
| Recruiting | MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS) NCT07374107 | Myositis International Health & Research Collaborative Alliance Foundation | — |
| Recruiting | A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathie NCT06698796 | Pfizer | Phase 3 |
| Recruiting | Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases NCT06685042 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults Wi NCT05979441 | argenx | Phase 3 |
| Unknown | Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopath NCT05833711 | Immunoforge Co. Ltd. | Phase 2 |
| Recruiting | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease NCT06347718 | Miltenyi Biomedicine GmbH | Phase 1 / Phase 2 |
| Terminated | Study of M5049 in DM and PM Participants (NEPTUNIA) NCT05650567 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Unknown | Plexin D1 as a Potential Biomarker inPM/DM NCT05637931 | Assiut University | — |
| Active Not Recruiting | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiop NCT05523167 | argenx | Phase 2 / Phase 3 |
| Completed | Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis NCT04976140 | Paean Biotechnology Inc. | Phase 1 / Phase 2 |
| Completed | Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) NCT04723303 | University of Florida | EARLY_Phase 1 |
| Active Not Recruiting | Add-on Intravenous Immunoglobulins in Early Myositis NCT05832034 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 2 / Phase 3 |
| Completed | Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties NCT05027152 | Federal University of Espirito Santo | N/A |
| Completed | High-intensity Strength Training in Myositis NCT04486261 | Rigshospitalet, Denmark | N/A |
| Completed | Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. NCT04628936 | Kezar Life Sciences, Inc. | Phase 2 |
| Recruiting | Rheumatology Patient Registry and Biorepository NCT04402086 | Yale University | — |
| Completed | A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyos NCT04033926 | Kezar Life Sciences, Inc. | Phase 2 |
| Terminated | A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Re NCT03981744 | Janssen Pharmaceutical K.K. | Phase 3 |
| Completed | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythemat NCT03817424 | Amgen | Phase 1 |
| Completed | Predictor of Clinical Response to Acthar in Myositis NCT03414086 | University of Pittsburgh | — |
| Unknown | Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis NCT03324152 | Karolinska University Hospital | N/A |
| Completed | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standa NCT02971683 | Bristol-Myers Squibb | Phase 3 |
| Unknown | PatientSpot Formerly Known as ArthritisPower NCT03840928 | Global Healthy Living Foundation | — |
| Completed | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis NCT02043548 | Chester Oddis | Phase 2 |
| Completed | Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy NCT02880527 | University Hospital, Rouen | — |
| Completed | Acthar in Treatment of Refractory Dermatomyositis and Polymyositis NCT01906372 | Rohit Aggarwal, MD | Phase 2 |
| Terminated | Efficacy and Tolerability of BAF312 in Patients With Polymyositis NCT01801917 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Dermatomyositis and Polymyositis Registry NCT01637064 | Phoenix Neurological Associates, LTD | — |
| Completed | Epidemiological Study of Inflammatory Myopathies in a French Region NCT02881450 | University Hospital, Strasbourg, France | — |
| Recruiting | Environmental Risk Factors for the Anti-synthetase Syndrome NCT01276470 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Abatacept Treatment in Polymyositis and Dermatomyositis NCT01315938 | Karolinska Institutet | Phase 2 |
| Completed | Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies NCT01432613 | Assistance Publique - Hôpitaux de Paris | N/A |
| Completed | Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis NCT01813617 | Karolinska University Hospital | — |
| Terminated | Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis NCT01148810 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM NCT00651040 | Institute of Rheumatology, Prague | Phase 3 |
| Completed | Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis NCT01415219 | University Hospital, Lille | Phase 2 |
| Completed | Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus NCT00504348 | Tokyo Medical and Dental University | Phase 2 / Phase 3 |
| Completed | Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/D NCT00335985 | Japan Blood Products Organization | Phase 3 |
| Completed | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) NCT00106184 | University of Pittsburgh | Phase 2 |
| Completed | Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases NCT00341679 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies NCT00213629 | University Hospital, Rouen | N/A |
| Completed | Anakinra in Myositis NCT01165008 | Karolinska Institutet | Phase 2 / Phase 3 |
| Completed | Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis NCT00033891 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Hand Function in Patients With Poly- or Dermatomyositis NCT00866125 | Karolinska Institutet | — |
| Completed | Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. NCT00138983 | UMC Utrecht | Phase 3 |
| Recruiting | Adult and Juvenile Myositis NCT00017914 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Methimazole to Treat Polymyositis and Dermatomyositis NCT00001421 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 2 |
| Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity NCT03941184 | Mayo Clinic | — |
| Completed | Genetic and Family Studies of Inherited Muscle Diseases NCT00001331 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Completed | Study and Treatment of Inflammatory Muscle Diseases NCT00001265 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | — |
| Completed | Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies NCT00001261 | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 |
| Completed | Ultrasound Evaluation of Tongue Movements in Speech and Swallowing NCT00001167 | National Institutes of Health Clinical Center (CC) | — |